质量法与酶活法检测血清脂蛋白相关磷脂酶A2在心脑血管疾病中的比较

宋来春

宋来春. 质量法与酶活法检测血清脂蛋白相关磷脂酶A2在心脑血管疾病中的比较[J]. 实用临床医药杂志, 2019, 23(20): 70-73. DOI: 10.7619/jcmp.201920019
引用本文: 宋来春. 质量法与酶活法检测血清脂蛋白相关磷脂酶A2在心脑血管疾病中的比较[J]. 实用临床医药杂志, 2019, 23(20): 70-73. DOI: 10.7619/jcmp.201920019
SONG Laichun. Quality method versus enzyme activity method in detection of serum lipoprotein-associated phospholipase A2 in cardiovascular and cerebrovascular diseases[J]. Journal of Clinical Medicine in Practice, 2019, 23(20): 70-73. DOI: 10.7619/jcmp.201920019
Citation: SONG Laichun. Quality method versus enzyme activity method in detection of serum lipoprotein-associated phospholipase A2 in cardiovascular and cerebrovascular diseases[J]. Journal of Clinical Medicine in Practice, 2019, 23(20): 70-73. DOI: 10.7619/jcmp.201920019

质量法与酶活法检测血清脂蛋白相关磷脂酶A2在心脑血管疾病中的比较

详细信息
  • 中图分类号: R743

Quality method versus enzyme activity method in detection of serum lipoprotein-associated phospholipase A2 in cardiovascular and cerebrovascular diseases

  • 摘要:
      目的  探讨质量法检测血清脂蛋白相关磷脂酶A2(Lp-PLA2)在急性心肌梗死和急性脑梗死中的诊断效能。
      方法  选取在心内科就诊的行血管造影并确诊的急性心肌梗死患者38例,急性脑梗死患者29例,体检健康者76例,收集血清以质量法和酶活法分别检测,分析两种方法的诊断效能。
      结果  急性心肌梗死组中,质量法检测结果为阳性36例、阴性2例,阳性率94.74%, 酶活法检测结果为阳性35例、阴性3例,阳性率92.11%, 2种检测方法诊断试验受试者工作特征曲线(ROC)曲线下面积分别为0.851、0.846。急性脑梗死组中,质量法检测结果为阳性24例、阴性5例,阳性率82.76%; 酶活法检测结果为阳性2例、阴性27例,阳性率6.90%, 2种检测方法诊断试验ROC曲线下面积分别为0.784、0.101。健康组76例均为阴性。2种方法检测急性心肌梗死无显著差异(P>0.05), 检测急性脑梗死则差异显著(P < 0.05)。
      结论  质量法检测血清Lp-PLA2在急性心肌梗死和急性脑梗死的诊断中具有较高的特异度与准确率,可作为急性心肌梗死和急性脑梗死的诊断方法,弥补了心血管造影的局限性。
    Abstract:
      Objective  To explore the clinical value of serum lipoprotein-associated phospholipase A2(Lp-PLA2)detected by quality method in cardiovascular and cerebrovascular diseases.
      Methods  A total of 38 patients confirmed as acute myocardial infarction undergoing angiography, 29 cases with acute cerebral infarction, and 76 healthy cases with physical examinations were selected. Serum was collected and their Lp-PLA2 levels were detected by quality method and enzyme activity method to analyze their diagnostic efficacy.
      Results  In the acute myocardial infarction group, 36 cases were positive and 2 cases were negative by quality method, with a positive rate of 94.74%. A total of 35 cases were positive and 3 cases were negative by enzyme activity method, with a positive rate of 92.11%. The area under the ROC curve of the two detection methods was 0.851 and 0.846, respectively. In the acute cerebral infarction group, 24 cases were positive and 5 cases were negative by quality method, with a positive rate of 82.76%. Two cases were positive and 27 cases were negative by enzyme activity method, with a positive rate of 6.90%. The area under the ROC curve of the two detection methods was 0.784 and 0.101, respectively. All the 76 cases in the healthy group were negative. There was no statistical difference between the two methods in the detection of acute myocardial infarction (P>0.05), but a significant difference was seen in the detection of acute cerebral infarction (P < 0.05).
      Conclusion  The detection of serum Lp-PLA2 by mass method has high specificity and accuracy in the diagnosis of acute myocardial infarction and acute cerebral infarction, which can be used as a diagnosis for acute myocardial infarction and acute cerebral infarction and makes up the limitations of angiography.
  • 表  1   3组基本信息及实验室检查结果比较(x±s)[n(%)]

    指标 急性心肌梗死组(n=38) 急性脑梗死组(n=29) 健康组(n=76)
    24(63.16) 17(58.62) 45(59.21)
    14(36.84) 12(41.38) 31(40.79)
    年龄/岁 51.22±11.38 60.14±9.86 50.45±10.95
    TC/(mmol/L) 5.17±0.82 5.04±0.36 4.10±0.65
    TG/(mmol/L) 1.92±0.96 1.89±0.55 1.16±0.63
    收缩压/mmHg 161.24±31.79 152.24±22.38 125.24±24.22
    质量法检测Lp-PLA2/(ng/mL) 245.61±99.91* 272.80±107.91* 106.41±80.35
    酶活法检测Lp-PLA2/(IU/L) 781.41±222.91* 553.37±223.49 508.51±200.91
    TC: 总胆固醇; TG: 甘油三酯。与健康组比较, *P < 0.05。
    下载: 导出CSV
  • [1] 中国老年学学会心脑血管病专业委员会, 中国医师协会检验医师分会心脑血管病专家委员会. 脂蛋白相关磷脂酶A2临床应用专家建议[J]. 中华心血管病杂志, 2015, 43(10): 843-847. doi: 10.3760/cma.j.issn.0253-3758.2015.10.002
    [2]

    Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies[J]. Lancet, 2010, 375(9725): 1536-1544. doi: 10.1016/S0140-6736(10)60319-4

    [3] 李铁威, 丛祥凤, 陈曦. 心血管疾病生物标志物: 脂蛋白相关磷脂酶A2的临床应用价值[J]. 中国循环杂志, 2016, 31(4): 410-413. doi: 10.3969/j.issn.1000-3614.2016.04.024
    [4]

    Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5): 923-931. doi: 10.1161/01.ATV.0000160551.21962.a7

    [5] 李灏, 黄金波, 蔡勇, 等. 急性期脑梗死血浆脂蛋白相关磷脂酶A2与颅内动脉狭窄的相关性研究[J]. 齐齐哈尔医学院学报, 2017, 38(2): 125-128. doi: 10.3969/j.issn.1002-1256.2017.02.001
    [6]

    Ballantyne C M, Hoogeveen R C, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study[J]. Circulation, 2004, 109(7): 837-842. doi: 10.1161/01.CIR.0000116763.91992.F1

    [7]

    Lin J X, Zheng H W, Cucchiara B L, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke[J]. Neurology, 2015, 85(18): 1585-1591. doi: 10.1212/WNL.0000000000001938

    [8]

    Wassertheil-Smoller S, McGinn A, Allison M, et al. Improvement in stroke risk prediction: role of C-reactive protein and lipoprotein-associated phospholipase A2 in the women's health initiative[J]. Int J Stroke, 2014, 9(7): 902-909. doi: 10.1111/j.1747-4949.2012.00860.x

    [9]

    Garg P K, McClelland R L, Jenny N S, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis[J]. Atherosclerosis, 2015, 241(1): 176-182. doi: 10.1016/j.atherosclerosis.2015.05.006

    [10]

    Kolodgie F, Burke A, Taye A, et al. Lipoproteinassociated phospholipase A2 is highly expressed in macrophages of coronary lesions prone to rupture[J]. Circulation, 2004, 110(3): 243-246.

    [11]

    Delgado P, Chacón P, Penalba A, et al. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting[J]. Atherosclerosis, 2012, 220(2): 532-536. doi: 10.1016/j.atherosclerosis.2011.11.016

    [12]

    Casas J P, Ninio E, Panayiotou A, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry[J]. Circulation, 2010, 121(21): 2284-2293. doi: 10.1161/CIRCULATIONAHA.109.923383

    [13]

    Zhuo S Q, Wolfert R L, Yuan C. Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A2 explain the discordance in results between the two assay methods[J]. Clin Biochem, 2017, 50(18): 1209-1215. doi: 10.1016/j.clinbiochem.2017.08.019

    [14] 程清. 脂蛋白相关磷脂酶A2和同型半胱氨酸水平与动脉粥样硬化性心脑血管疾病关系的研究[J]. 检验医学, 2015, 30(1): 40-43. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY201501013.htm
    [15]

    Oei H H, van der Meer I M, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study[J]. Circulation, 2005, 111(5): 570-575. doi: 10.1161/01.CIR.0000154553.12214.CD

    [16]

    Millwood I Y, Bennett D A, Walters R G, et al. Lipoprotein-associated phospholipase A2 loss-of-function variant and risk of vascular diseases in 90, 000 Chinese adults[J]. J Am Coll Cardiol, 2016, 67(2): 230-231. doi: 10.1016/j.jacc.2015.10.056

    [17] 陆梦丽, 吕礼应. 脂蛋白相关磷脂酶A2检测方法及其临床应用进展[J]. 国际检验医学杂志, 2018, 39(18): 2313-2316, 2334. doi: 10.3969/j.issn.1673-4130.2018.18.031
    [18] 杨洁飞, 梁指荣, 苏锡康. 脂蛋白相关磷脂酶A2检测在急性冠脉综合征中的临床应用[J]. 实验与检验医学, 2015, 33(3): 357-359. doi: 10.3969/j.issn.1674-1129.2015.03.041
    [19] 陈建林, 胡金伦, 温宇明, 等. 脂蛋白相关的磷脂酶A2与脑血管意外的相关研究及其临床应用价值[J]. 现代中西医结合杂志, 2011, 20(25): 3172-3173. doi: 10.3969/j.issn.1008-8849.2011.25.028
    [20] 丁梦蕾, 孙立山, 范列英. 脂蛋白相关磷脂酶A2在老年冠心病患者中的临床应用价值[J]. 老年医学与保健, 2018(4): 364-366, 371. doi: 10.3969/j.issn.1008-8296.2018.04.003
    [21] 杨琴. 血浆脂蛋白相关磷脂酶A2检测在冠状动脉粥样硬化中的应用价值[J]. 西部医学, 2013, 25(5): 784-785, 788. doi: 10.3969/j.issn.1672-3511.2013.05.057
  • 期刊类型引用(16)

    1. 杨小燕,陈雅彬,余小丽,黄前进,游秀华. 精准护理干预在声带息肉患者围手术期的应用效果. 中国当代医药. 2023(09): 188-191 . 百度学术
    2. 刘沛,程呈,王虹. 基于ICF及ICHI构建发声功能康复训练对声带息肉摘除术后患者嗓音嘶哑程度、声学指标及发声功能的影响. 河南外科学杂志. 2022(01): 25-27 . 百度学术
    3. 何月,李玉婧. 以行为计划理论为基础的护理模式对声带息肉手术患者自我管理能力的影响. 黑龙江医学. 2022(18): 2289-2291 . 百度学术
    4. 刘思明,孔佳佳,韦桂欢. 声乐系学生声带损伤的中西医结合治疗. 微创医学. 2021(02): 228-230 . 百度学术
    5. 岳荟. 规范化护理模式用于声带息肉患者术后的效果研究. 心理月刊. 2020(02): 26+28 . 百度学术
    6. 张巧真,吴志芳,余朝阳. 临床护理路径降低声带息肉手术患者术后并发症的临床研究. 系统医学. 2020(12): 168-170 . 百度学术
    7. 郭海英. 优质护理干预配合雾化器雾化对声带息肉支撑喉镜下手术患者术后嗓音恢复的影响. 医学理论与实践. 2020(22): 3855-3857 . 百度学术
    8. 李晓玲. 规范化护理干预在声带息肉患者术后的应用观察. 临床研究. 2019(02): 153-155 . 百度学术
    9. 李希曼. 优质护理在声带息肉患者术后嗓音康复中的应用及对喉发声能力自主评分的效果. 中外医学研究. 2019(03): 96-98 . 百度学术
    10. 王晶. 声带息肉住院患者护理中临床护理路径的应用. 继续医学教育. 2019(10): 88-90 . 百度学术
    11. 孙伟. 全麻喉罩电子喉镜下声带息肉摘除术的全程性护理. 实用临床医药杂志. 2018(18): 66-68 . 本站查看
    12. 罗婷,刘名玉. 声带息肉的临床诊疗进展. 医疗装备. 2018(10): 203-204 . 百度学术
    13. 岳蕊蕊,叶婷婷,李新歌. 质控管理措施对声带息肉摘除术患者的干预效果分析. 中国药物与临床. 2018(04): 655-656 . 百度学术
    14. 张霞,张晓,程大鹏. 失效模式与效应分析模式的护理干预对声带息肉术后患者生活质量及护理满意度的影响. 中国药物与临床. 2018(04): 667-669 . 百度学术
    15. 高红. 临床护理路径在声带息肉患者护理中的应用价值分析. 实用临床护理学电子杂志. 2017(49): 173+177 . 百度学术
    19. 侯玉环. 规范化优质护理对声带息肉摘除术患者住院情况及生存质量的影响. 家庭医药.就医选药. 2017(12): 34-35 . 百度学术

    其他类型引用(6)

表(1)
计量
  • 文章访问数:  179
  • HTML全文浏览量:  117
  • PDF下载量:  5
  • 被引次数: 22
出版历程
  • 收稿日期:  2019-08-12
  • 修回日期:  2019-09-14
  • 网络出版日期:  2021-02-28
  • 发布日期:  2019-10-27

目录

    /

    返回文章
    返回
    x 关闭 永久关闭